Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in via BSG
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
About
Hosted content
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
About
Hosted content
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in via BSG
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 64, Issue 6
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Inflammatory bowel disease
Original article
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study
Online download statistics by month:
Online download statistics by month: January 2015 to February 2024
Abstract
Full
Pdf
Jan 2015
619
65
100
Feb 2015
123
18
24
Mar 2015
64
14
19
Apr 2015
47
18
24
May 2015
1329
25
118
Jun 2015
638
37
64
Jul 2015
269
30
40
Aug 2015
154
20
23
Sep 2015
146
17
17
Oct 2015
70
22
21
Nov 2015
91
15
10
Dec 2015
59
9
5
Jan 2016
67
9
9
Feb 2016
58
13
14
Mar 2016
36
7
7
Apr 2016
42
9
9
May 2016
68
14
13
Jun 2016
56
6
7
Jul 2016
63
7
14
Aug 2016
45
10
8
Sep 2016
52
13
10
Oct 2016
51
10
11
Nov 2016
30
9
6
Dec 2016
34
5
2
Jan 2017
27
5
6
Feb 2017
27
8
6
Mar 2017
25
12
11
Apr 2017
19
11
4
May 2017
28
17
11
Jun 2017
50
15
8
Jul 2017
82
9
6
Aug 2017
77
6
4
Sep 2017
71
9
7
Oct 2017
96
8
4
Nov 2017
51
4
2
Dec 2017
72
8
9
Jan 2018
84
7
1
Feb 2018
86
12
5
Mar 2018
89
14
4
Apr 2018
113
10
7
May 2018
76
9
4
Jun 2018
122
22
9
Jul 2018
67
4
3
Aug 2018
66
6
3
Sep 2018
46
3
2
Oct 2018
54
6
3
Nov 2018
76
12
3
Dec 2018
86
4
2
Jan 2019
85
4
1
Feb 2019
45
6
5
Mar 2019
108
3
3
Apr 2019
20
8
5
May 2019
64
10
4
Jun 2019
51
8
2
Jul 2019
69
13
8
Aug 2019
72
6
2
Sep 2019
59
2
3
Oct 2019
64
11
10
Nov 2019
58
4
1
Dec 2019
52
4
1
Jan 2020
50
3
3
Feb 2020
58
4
0
Mar 2020
32
1
0
Apr 2020
87
9
3
May 2020
54
6
4
Jun 2020
60
6
5
Jul 2020
151
12
10
Aug 2020
43
4
3
Sep 2020
106
12
8
Oct 2020
69
6
3
Nov 2020
62
6
5
Dec 2020
83
5
3
Jan 2021
91
11
3
Feb 2021
209
5
2
Mar 2021
93
5
3
Apr 2021
90
3
0
May 2021
74
8
6
Jun 2021
23
22
7
Jul 2021
6
6
1
Aug 2021
9
6
3
Sep 2021
6
5
4
Oct 2021
57
5
4
Nov 2021
86
12
8
Dec 2021
243
8
5
Jan 2022
91
7
3
Feb 2022
101
5
4
Mar 2022
137
4
2
Apr 2022
141
10
4
May 2022
83
8
4
Jun 2022
121
8
3
Jul 2022
150
8
3
Aug 2022
74
10
3
Sep 2022
89
9
4
Oct 2022
93
4
2
Nov 2022
117
6
1
Dec 2022
85
4
2
Jan 2023
108
10
5
Feb 2023
226
8
4
Mar 2023
115
8
5
Apr 2023
59
7
2
May 2023
83
10
4
Jun 2023
50
10
3
Jul 2023
88
2
5
Aug 2023
146
6
2
Sep 2023
73
4
2
Oct 2023
185
6
1
Nov 2023
378
8
1
Dec 2023
133
3
3
Jan 2024
192
4
4
Feb 2024
138
4
3
Total
11646
1045
916
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in via BSG
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?